WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

(SHANGHAI, March 18, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 (“Reporting Period”)

2024/02/20

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

PHILADELPHIA, PA. February 20, 2024 – WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.

2024/02/04

An Open Letter to our Customers from WuXi AppTec Leadership

For more than 20 years, WuXi AppTec has enabled thousands of customers across the pharmaceutical and life sciences industries to discover, develop, and manufacture new medicines to benefit patients.

Events

2024/01/31

Digital WuXi Global Forum 2024

Following the resounding success of the 12th annual WuXi Global Forum during JPM2024, we're bringing the experience online for colleagues around the world unable to attend in person. Join us for the Digital WuXi Global Forum 2024 on Jan 31, to be premiered at 7:00-11:30 AM and 7:00-11:30 PM PST respectively.

2024/01/09

WuXi Global Forum 2024

The theme of this year’s forum is B.O.L.D. We reflected on the state of innovation and highlighted our industry’s notable advances in tackling innovation challenges to build an impactful future for patients: Breaking Barriers, Opening New Horizons, Leading Next Generation and Delivering on the Promise for Patients.

2023/10/26

BOLD Innovation That Matters: Episode 4

We recognize the pivotal roles breakthrough science plays in transforming patients' lives, and the challenges in bridging the gap between science and development. It is our pleasure to invite you to an exclusive global online event dedicated to unraveling this very conundrum: Translating Science into Meaningful Therapies.

Innovation that Matters

WuXi AppTec

Global Platform
One Vision

Our Vision

Every Drug Can Be Made
and Every Disease Can Be Treated

Our Values

Integrity & Dedication, Working Together & Sharing Success;
Doing the Right Thing, Doing It Right.

News

Overview

News

Environmental, Social and Governance (ESG)

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

An Open Letter to our Customers from WuXi AppTec Leadership

Digital WuXi Global Forum 2024

WuXi Global Forum 2024

BOLD Innovation That Matters: Episode 4